No Data
Express News | Lyra Therapeutics Inc - Topline Results From Enlighten 2 Expected in Q2 2025
Express News | Lyra Therapeutics Fully Enrolls Pivotal Phase 3 Enlighten 2 Trial of Lyr-210 for the Treatment of Chronic Rhinosinusitis
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
Lyra Health Selected for BenefitsPRO's 2024 Luminaries Awards
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
Lyra Health and Hazelden Betty Ford Foundation Announce Comprehensive Care Program for Individuals and Families Struggling With Substance Use Disorder
No Data
No Data